Series B round financing to unveil proof-of-concepts of both ART-648 and ART-001 programs
YOKOHAMA, January 15, 2021 – ARTham Therapeutics Inc. (“ARTham”), a clinical stage biopharmaceutical company, has raised 590 million JPY (approx. $5.7 million) in Series B financing lead by Miyako Capital and joined by additional investors including Takeda Pharmaceutical Company, SMBC Venture Capital, Mizuho Capital, Oita Venture Capital and Yokohama Capital.
Phase I clinical trials for both ART-648 and ART-001 have been successfully completed and Phase II trials for these programs are planned to initiate during the second half of 2021. The funds accelerate ARTham’s R&D towards achieving clinical POC of ART-648 and ART-001 for bullous pemphigoid and slow-flow vascular malformations, respectively.
About ARTham Therapeutics
ARTham Therapeutics is a clinical stage biopharmaceutical company that will deliver “medicines that matter” for patients, with a compelling portfolio developed through unraveling hidden value of existing pharma assets. ARTham is a virtual R&D company that seeks the best academic and business partners to rapidly develop high value clinical candidates. The company is headquartered in Yokohama, Japan. For more information, please visit https://www.arthamther.com/en/